Premenopozal kadınlarda comt(katekol o-metiltransferaz) ve nq01(nad(p)h Kinon oksidoredüktaz) enzim polimorfizmlerinin östrojen reseptörü pozitif meme kanseri ile ilişkisi
Küçük Resim Yok
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Maltepe Üniversitesi, Lisansüstü Eğitim Enstitüsü
Erişim Hakkı
CC0 1.0 Universal
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Özet
Meme kanseri etiyolojisinde hiperöstrojenizm önemli bir risk faktörüdür. Östrojen metabolizması ve inaktivasyonundan sorumlu en önemli iki faz II enzim; catechol O metiltransferaz (COMT) ve NAD(P)H kinon oksidoredüktaz (NQO1)’dır. COMT ve NQO1 enzimlerine ait polimorfizmin meme kanseri ile ilişkisi daha önce pek çok etnik popülasyonda yapılan çalışmalarda incelenmiş ve değişik sonuçlar elde edilmiştir. Daha önce yapılan çalışmalarda da gösterilmiş olan belli polimorfizmlerde enzim aktivitesi normalin 3’te 1’ine hatta 4’te 1’ine azalmaktadır. (3-7) Bu çalışmada ailede meme kanseri hikayesi bulunmayan, premenopozal, östrojen reseptör (+) 50 meme kanseri hastası ve 50 kontrol grubu sağlıklı kadında COMT ve NQO1 enzim polimorfizmleri ile meme kanseri arasındaki ilişki incelenmiştir. Meme kanseri olan hasta grubunda COMT enziminde homozigot ve heterozigot mutasyonu olanların oranı %66, sağlıklı kontrol grubunda ise homozigot ve heterozigot mutasyon oranı %84 olarak saptanmıştır. Ayrıca meme kanserli hasta grubunda NQO1 enzim homozigot ve heterozigot mutasyon oranı %42, kontrol grubunda ise bu oran %68 olarak saptanmıştır. Her iki enzimde saptanan, COMT ve NQO1 enzimlerinin hızını azaltan homozigot ve heterozigot mutasyonlar ile meme kanseri arasında ilişki saptanmamıştır. Sonuç olarak, literatürde pek çok etnik grupta saptandığı gibi Türk popülasyonunda da COMT ve NQO1 enzimlerinin düşük aktiviteli allelleri ile meme kanseri riski arasında ilişki saptanmamıştır.
Hyperestrogenism is an important risk factor in breast cancer etiology. The two most important phase II enzymes, responsible for estrogen metabolism and inactivation is; catechol O methyltransferase (COMT) and NAD (P) H quinone oxidoreductase (NQO1). The relationship between polymorphism of COMT and NQO1 enzymes and breast cancer has been previously studied in many ethnic populations and different results have been obtained. As shown in previous studies; with these certain polymorphisms enzyme activity decreases to 1 in 3 or even 1 in 4 of normal. In this study, the relationship between COMT and NQO1 enzyme polymorphisms and breast cancer was invastigated in 50 premenopausal, estrogen receptor (+) breast cancer patients with no family history of breast cancer and 50 control group of healthy women. The rate of those with homozygous and heterozygous mutations in COMT enzyme in the breast cancer patient group was 66%, and the rate of homozygous and heterozygous mutations in the healthy control group was 84%. In addition, the NQO1 enzyme homozygous and heterozygous mutation rate was 42% in the breast cancer patient group and 68% in the control group. No relationship was found between breast cancer and homozygous and heterozygous mutations detected in both enzymes, reducing the rate of COMT and NQO1 enzymes. In conclusion, as seen in many study made in different ethnic groups in the literature; there is no relationship between low activity alleles of COMT and NQO1 enzymes and breast cancer risk in the Turkish population.
Hyperestrogenism is an important risk factor in breast cancer etiology. The two most important phase II enzymes, responsible for estrogen metabolism and inactivation is; catechol O methyltransferase (COMT) and NAD (P) H quinone oxidoreductase (NQO1). The relationship between polymorphism of COMT and NQO1 enzymes and breast cancer has been previously studied in many ethnic populations and different results have been obtained. As shown in previous studies; with these certain polymorphisms enzyme activity decreases to 1 in 3 or even 1 in 4 of normal. In this study, the relationship between COMT and NQO1 enzyme polymorphisms and breast cancer was invastigated in 50 premenopausal, estrogen receptor (+) breast cancer patients with no family history of breast cancer and 50 control group of healthy women. The rate of those with homozygous and heterozygous mutations in COMT enzyme in the breast cancer patient group was 66%, and the rate of homozygous and heterozygous mutations in the healthy control group was 84%. In addition, the NQO1 enzyme homozygous and heterozygous mutation rate was 42% in the breast cancer patient group and 68% in the control group. No relationship was found between breast cancer and homozygous and heterozygous mutations detected in both enzymes, reducing the rate of COMT and NQO1 enzymes. In conclusion, as seen in many study made in different ethnic groups in the literature; there is no relationship between low activity alleles of COMT and NQO1 enzymes and breast cancer risk in the Turkish population.
Açıklama
Anahtar Kelimeler
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Atasoy, I. (2020). Premenopozal kadınlarda comt(katekol o-metiltransferaz) ve nq01(nad(p)h Kinon oksidoredüktaz) enzim polimorfizmlerinin östrojen reseptörü pozitif meme kanseri ile ilişkisi (Yayımlanmamış Yüksek Lisans Tezi). Maltepe Üniversitesi, Lisansüstü Eğitim Enstitüsü, İstanbul.
